Isolated pathogen | Resistant rate (%) | pvalue | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | Overall | ||
Staphylococcus aureus, n | 74 | 47 | 38 | 26 | 18 | 7 | 20 | 17 | 9 | 256 | |
Methicillin–R S. aureus | 94.6 | 91.5 | 100 | 96.2 | 100 | 85.7 | 100 | 94.1 | 77.8 | 94.9 | 0.414 |
Escherichia coli, n | 12 | 9 | 9 | 11 | 8 | 6 | 7 | 8 | 8 | 78 | |
Ceftriaxone–R E. coli | 50 | 22.2 | 22.2 | 18.2 | 50 | 33.3 | 28.6 | 62.5 | 50 | 37.2 | 0.314 |
Ceftazidime–R E. coli | 25 | 22.2 | 33.3 | 18.2 | 62.5 | 33.3 | 42.9 | 62.5 | 50 | 37.2 | 0.039* |
Ciprofloxacin–R E. coli | – | 22.2 | 33.3 | 54.5 | 75 | 83.3 | 71.4 | 87.5 | 37.5 | 47.4 | 0.046* |
ESBL E. coli | – | – | – | – | – | – | 14.3 | 50.0 | 50.0 | 39.1 | 0.176 |
Klebsiella pneumoniae, n | 9 | 16 | 9 | 8 | 17 | 8 | 14 | 17 | 11 | 109 | |
Ceftriaxone–R K. pneumoniae | 66.7 | 18.8 | 55.6 | 75 | 52.9 | 75 | 71.4 | 88.2 | 36.4 | 58.7 | 0.053 |
Ceftazidime–R K. pneumoniae | 22.2 | 25.0 | 44.4 | 75 | 76.5 | 75 | 71.4 | 88.2 | 36.4 | 58.7 | 0.002* |
Ciprofloxacin–R K. pneumoniae | – | 43.8 | 33.3 | 37.5 | 70.6 | 50 | 78.6 | 58.8 | 27.3 | 48.6 | 0.507 |
ESBL K. pneumoniae | – | – | – | – | – | – | 42.9 | 64.7 | 27.3 | 47.6 | 0.532 |
Pseudomonas aeruginosa, n | 25 | 14 | 15 | 16 | 16 | 23 | 21 | 23 | 18 | 171 | |
Ceftazidime–R P. aeruginosa | 24 | 14.3 | 13.3 | 12.5 | 6.3 | 26.1 | 28.6 | 17.4 | 16.7 | 18.7 | 0.846 |
Cefepime–R P. aeruginosa | – | – | – | 6.3 | 6.3 | 0 | 0 | 0 | 11.1 | 2.3 | 0.715 |
Imipenem–R P. aeruginosa | 8 | 14.3 | 6.7 | 0 | 12.5 | 22 | 0 | 0 | 16.7 | 8.8 | 0.812 |
Acinetobacter baumannii, n | 22 | 32 | 28 | 33 | 21 | 19 | 23 | 21 | 26 | 225 | |
Imipenem–R A. baumannii | 0 | 9.4 | 7.1 | 30.3 | 38.1 | 15.8 | 17.4 | 14.3 | 65.4 | 22.2 | <0.001* |